|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WNK1 |
Gene summary for WNK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WNK1 | Gene ID | 65125 |
| Gene name | WNK lysine deficient protein kinase 1 | |
| Gene Alias | HSAN2 | |
| Cytomap | 12p13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q9H4A3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65125 | WNK1 | CA_HPV_1 | Human | Cervix | CC | 1.54e-05 | -1.65e-01 | 0.0264 |
| 65125 | WNK1 | CA_HPV_3 | Human | Cervix | CC | 1.36e-11 | 4.07e-01 | 0.0414 |
| 65125 | WNK1 | N_HPV_2 | Human | Cervix | N_HPV | 3.04e-02 | 1.85e-01 | -0.0131 |
| 65125 | WNK1 | CCI_1 | Human | Cervix | CC | 5.31e-03 | 4.78e-01 | 0.528 |
| 65125 | WNK1 | CCI_2 | Human | Cervix | CC | 1.10e-11 | 1.71e+00 | 0.5249 |
| 65125 | WNK1 | CCI_3 | Human | Cervix | CC | 4.70e-19 | 1.53e+00 | 0.516 |
| 65125 | WNK1 | L1 | Human | Cervix | CC | 5.44e-03 | -3.17e-01 | 0.0802 |
| 65125 | WNK1 | T1 | Human | Cervix | CC | 2.33e-04 | -3.66e-01 | 0.0918 |
| 65125 | WNK1 | LZE4T | Human | Esophagus | ESCC | 1.02e-09 | 1.35e-01 | 0.0811 |
| 65125 | WNK1 | LZE7T | Human | Esophagus | ESCC | 4.65e-09 | 6.89e-01 | 0.0667 |
| 65125 | WNK1 | LZE8T | Human | Esophagus | ESCC | 6.08e-10 | 2.88e-01 | 0.067 |
| 65125 | WNK1 | LZE20T | Human | Esophagus | ESCC | 1.31e-03 | 2.63e-01 | 0.0662 |
| 65125 | WNK1 | LZE22D1 | Human | Esophagus | HGIN | 4.55e-03 | -9.79e-02 | 0.0595 |
| 65125 | WNK1 | LZE24T | Human | Esophagus | ESCC | 8.84e-13 | 4.95e-01 | 0.0596 |
| 65125 | WNK1 | LZE21T | Human | Esophagus | ESCC | 3.48e-02 | 1.70e-01 | 0.0655 |
| 65125 | WNK1 | P1T-E | Human | Esophagus | ESCC | 5.74e-05 | 5.83e-01 | 0.0875 |
| 65125 | WNK1 | P2T-E | Human | Esophagus | ESCC | 1.14e-44 | 8.58e-01 | 0.1177 |
| 65125 | WNK1 | P4T-E | Human | Esophagus | ESCC | 8.41e-33 | 9.46e-01 | 0.1323 |
| 65125 | WNK1 | P5T-E | Human | Esophagus | ESCC | 3.52e-25 | 3.63e-01 | 0.1327 |
| 65125 | WNK1 | P8T-E | Human | Esophagus | ESCC | 1.08e-27 | 5.68e-01 | 0.0889 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
| GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
| GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
| GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
| GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
| GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
| GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
| GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
| GO:00224084 | Cervix | CC | negative regulation of cell-cell adhesion | 48/2311 | 196/18723 | 1.99e-06 | 6.18e-05 | 48 |
| GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
| GO:005134810 | Cervix | CC | negative regulation of transferase activity | 60/2311 | 268/18723 | 2.77e-06 | 8.02e-05 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WNK1 | SNV | Missense_Mutation | novel | c.3772T>C | p.Ser1258Pro | p.S1258P | Q9H4A3 | protein_coding | tolerated_low_confidence(0.91) | benign(0) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WNK1 | SNV | Missense_Mutation | rs756361196 | c.1726N>T | p.Arg576Trp | p.R576W | Q9H4A3 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WNK1 | SNV | Missense_Mutation | rs754884163 | c.2225A>C | p.His742Pro | p.H742P | Q9H4A3 | protein_coding | tolerated_low_confidence(0.23) | benign(0.062) | TCGA-A7-A4SB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | CR |
| WNK1 | SNV | Missense_Mutation | c.2534N>A | p.Arg845His | p.R845H | Q9H4A3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WNK1 | SNV | Missense_Mutation | rs770856927 | c.5228N>T | p.Ser1743Leu | p.S1743L | Q9H4A3 | protein_coding | tolerated_low_confidence(0.07) | benign(0.077) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WNK1 | SNV | Missense_Mutation | c.1162N>C | p.Glu388Gln | p.E388Q | Q9H4A3 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| WNK1 | SNV | Missense_Mutation | rs754884163 | c.2225A>C | p.His742Pro | p.H742P | Q9H4A3 | protein_coding | tolerated_low_confidence(0.23) | benign(0.062) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| WNK1 | SNV | Missense_Mutation | novel | c.1121T>A | p.Leu374Gln | p.L374Q | Q9H4A3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A6IV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WNK1 | SNV | Missense_Mutation | novel | c.6390N>C | p.Glu2130Asp | p.E2130D | Q9H4A3 | protein_coding | tolerated(0.08) | benign(0.437) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WNK1 | SNV | Missense_Mutation | novel | c.3457N>T | p.Pro1153Ser | p.P1153S | Q9H4A3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.935) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 65125 | WNK1 | SERINE THREONINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 252827493 | ||
| 65125 | WNK1 | SERINE THREONINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, KINASE, DRUGGABLE GENOME, ENZYME | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 18591455 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |